Welsh drug body issues new recommendations

The All Wales Medicines Strategy Group (AWMSG) has accepted darunavir (Prezista), co-administered with low-dose ritonavir, for use within NHS Wales in treatment-naïve patients with HIV-1 infection.

The following two drugs were rejected by the AWMSG on the grounds of unproven cost-effectiveness:

  • Ranolazine (Ranexa) for stable angina pectoris.
  • Degarelix (Firmagon) for advanced hormone-dependent prostate cancer.

Firmagon was previously rejected by the Scottish Medicines Consortium (SMC) for the same indication.

Further information: AWMSG

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases